Compare OSPN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ZURA |
|---|---|---|
| Founded | 1991 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 435.0M |
| IPO Year | 2000 | N/A |
| Metric | OSPN | ZURA |
|---|---|---|
| Price | $10.55 | $6.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $16.67 | $11.78 |
| AVG Volume (30 Days) | ★ 550.2K | 457.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $5.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $0.99 |
| 52 Week High | $18.13 | $7.25 |
| Indicator | OSPN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 45.86 |
| Support Level | $10.26 | $5.62 |
| Resistance Level | $11.68 | $6.90 |
| Average True Range (ATR) | 0.41 | 0.52 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 31.75 | 0.98 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.